原始来源记录
Verrica 在中期分析显示无需额外患者后,完成了 YCANTH 用于寻常疣的两项全球 3 期关键试验中的第一项 (COVE-2) 的入组。两项试验的顶线数据预计分别在 2027 年第一季度和 2027 年中期。本文是对 2026 年 8 月 27 日在 2026 年第三季度收益发布中的公告的回顾。
EX-99.1 2 d144356dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results – Company reports record U.S. YCANTH net product revenue of $5.7 million in Q3 2026, up 11.9% over the previous quarter and 57.9% year-over-year, and total revenue of $6.9 million – – Enrollment completed in the first of two pivotal trials in the global Phase 3 common warts program, with topline data for each trial expected in Q1 2027 and mid-2027, respectively – – Company achieved pre-defined revenue, growth and operational milestones under credit facility to unlock full access to $27.5 million of non-dilutive growth capital and further extend cash runway through data readout for both common warts trials – – Company is now exploring the development of its onc